Details for New Drug Application (NDA): 204822
✉ Email this page to a colleague
NDA 204822 describes IZBA, which is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the IZBA profile page.
The generic ingredient in IZBA is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.
The generic ingredient in IZBA is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.
Summary for 204822
| Tradename: | IZBA |
| Applicant: | Novartis |
| Ingredient: | travoprost |
| Patents: | 4 |
Medical Subject Heading (MeSH) Categories for 204822
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.003% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | May 15, 2014 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Oct 10, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Subscribe | Patent Expiration: | Oct 10, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Subscribe | Patent Expiration: | May 19, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
